Company patents
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. demonstrates a primary focus on "Heterocyclic Compounds" (89.8% of its portfolio), yet surprisingly, this core area has seen a significant decline of 28.6% so far in 2026. Concurrently, the company shows an emerging interest in "Foods & Beverages," which experienced a remarkable 700.0% growth in 2025, suggesting a potential diversification beyond its traditional pharmaceutical emphasis.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
59 US filings (since 2023) · 6 categories · 5 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Patents
Showing 1-10 of 87